BridgeBio Oncology Therapeutics Inc.
NASDAQ Global MarketTotal Valuation
BridgeBio Oncology Therapeutics Inc. carries a market capitalization of 228.50M, placing it among publicly traded companies globally. Its enterprise value stands at 387.28M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 228.50M |
| Enterprise Value | 387.28M |
Share Statistics
BridgeBio Oncology Therapeutics Inc. currently has 80.12M shares outstanding.
| Shares Outstanding | 80.12M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 1.89 |
| P/TBV Ratio | 1.89 |
| P/FCF Ratio | -1.56 |
| P/OCF Ratio | -1.56 |
Financial Position
BridgeBio Oncology Therapeutics Inc. maintains a current ratio of 4.69, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.69 |
| Quick Ratio | 4.38 |
| Debt / Equity | 0.78 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -51.46 |
| Return on Assets (ROA) | -68.99 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
BridgeBio Oncology Therapeutics Inc.'s stock has declined approximately -74.66667% over the past 52 weeks. The 50-day moving average sits at 6.17, while the 200-day moving average is 8.56.
| Beta (5Y) | N/A |
| 52-Week Price Change | -74.66667% |
| 50-Day Moving Average | 6.17 |
| 200-Day Moving Average | 8.56 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -198.20M, while operating income came in at -198.95M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -198.95M |
| Pretax Income | -182.11M |
| Net Income | -182.11M |
| EBITDA | -198.20M |
| EBIT | -198.95M |
| Earnings Per Share (EPS) | -5.89 |
Balance Sheet
BridgeBio Oncology Therapeutics Inc. holds 225.71M in cash and equivalents against 2.51M in total debt, resulting in a net debt position of -54.06M. Total book value stands at 323.11M, with working capital of 190.74M providing operational flexibility.
| Cash & Cash Equivalents | 225.71M |
| Total Debt | 2.51M |
| Net Debt | -54.06M |
| Equity (Book Value) | 323.11M |
| Book Value Per Share | 4.03 |
| Working Capital | 190.74M |
Cash Flow
BridgeBio Oncology Therapeutics Inc. produced -151.28M in operating cash flow over the past twelve months. After subtracting -284,000.00 in capital expenditures, free cash flow totaled -151.56M - equivalent to -4.90 per share.
| Operating Cash Flow | -151.28M |
| Capital Expenditures | -284,000.00 |
| Free Cash Flow | -151.56M |
| FCF Per Share | -4.90 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -59.82 |
| FCF Yield | -64.11 |
Scores
BridgeBio Oncology Therapeutics Inc. posts an Altman Z-Score of 4.01, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.01 |